Could a Brain-Targeting drug ease Parkinson's dementia symptoms?

NCT ID NCT04470037

Completed Disease control Sponsor: China Medical University Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This completed Phase 2 trial tested a drug called DAAOI-P in 61 people with Parkinson's disease who also have dementia. The goal was to see if the drug could improve walking, reduce falls, and ease neuropsychiatric symptoms. Participants received either DAAOI-P or a placebo pill for a period, and changes were measured using standard rating scales.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: DAAOI-P (a drug that modulates NMDA receptors)
What this could lead to: If successful, DAAOI-P could offer a new treatment option to improve movement and behavioral symptoms in people with Parkinson's dementia.
What could go wrong: This is a small Phase 2 trial with only 61 participants, so results may not apply to everyone. The drug may not show clear benefits or could have side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PARKINSON DISEASE DEMENTIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

dementia Lewy body dementia Parkinson disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PARKINSON'S DISEASE WITH DEMENTIA

Contacts and locations

Locations

Department of Psychiatry, China Medical University Hospital

Taichung, Taiwan

More trials for these conditions

Other studies related to the condition(s) this trial covers.